18 Years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma
Open Access
- 1 October 2005
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (10) , 1306-1310
Abstract
Aim: To analyse local tumour control, radiation related complications, visual acuity, enucleation rate, and survival after brachytherapy of small to medium sized choroidal melanoma (CM) with a high dose rate (HDR) strontium-90 (Sr-90) applicator. Methods: From 1983 until 2000, 98 eyes with CM were treated with Sr-90 brachytherapy. The main outcome measures were actuarial rates of the patients’ survival, ocular conservation rate, tumour regression, complication rates, and preservation of visual acuity. End point rates were estimated using Kaplan-Meier analysis. Results: The median follow up time was 6.7 years (0.5–18.8 years). Actuarial melanoma free patient survival rate was 85% (SE 4.8%) after 18 years. Actuarial rate of ocular conservation and complete tumour regression was 90% (SE 3.8%) after 15 years. In 93% local tumour control was achieved, 88% showed a stable scar. Recurrence of the tumour on the border caused enucleation of six eyes (7%). In three cases (4%) retinal detachment was the end point. No cases of optic atrophy or of sight impairing retinopathy outside the treated area were found. Actuarial rate of preservation of visual acuity of 1/10 was 65% at 5 years and 45% at 15 years of follow up (SE 5.9% and 8.8%). Conclusions: Sr-90 brachytherapy is as effective as iodine or ruthenium brachytherapy for small to medium sized CM but causes fewer complications. The preservation of vision is better than with all other described radioisotopes. HDR Sr-90 brachytherapy can therefore safely be recommended for small to medium sized CM.Keywords
This publication has 29 references indexed in Scilit:
- Very Long-Term Prognosis of Patients with Malignant Uveal MelanomaInvestigative Ophthalmology & Visual Science, 2003
- The COMS randomized trial of iodine 125 brachytherapy for choroidal melanomaOphthalmology, 2002
- Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group studyBritish Journal of Ophthalmology, 2001
- Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma I. visual acuity after 3 years COMS report no. 16Ophthalmology, 2001
- Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanomaOphthalmology, 1999
- Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanomaActa Ophthalmologica Scandinavica, 1997
- Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.British Journal of Ophthalmology, 1996
- An approach to the management of patients with uveal melanomaEye, 1993
- Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years' experience.British Journal of Ophthalmology, 1986
- 10 Jahre Erfahrung mit der Ruthenium-106/Rhodium-106-Behandlung des malignen Melanoms der Aderhaut - Bericht über 264 bestrahlte TumorenKlinische Monatsblätter für Augenheilkunde, 1986